[go: up one dir, main page]

WO2003106421A3 - PHENYLALKYLAMINES AND PYRIDYLALKYLAMINES - Google Patents

PHENYLALKYLAMINES AND PYRIDYLALKYLAMINES Download PDF

Info

Publication number
WO2003106421A3
WO2003106421A3 PCT/EP2003/006290 EP0306290W WO03106421A3 WO 2003106421 A3 WO2003106421 A3 WO 2003106421A3 EP 0306290 W EP0306290 W EP 0306290W WO 03106421 A3 WO03106421 A3 WO 03106421A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
alkynyl
alkenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006290
Other languages
French (fr)
Other versions
WO2003106421A2 (en
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Riva
Luciano Guarneri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Recordati Industria Chimica e Farmaceutica SpA
Original Assignee
Recordati SA
Recordati Industria Chimica e Farmaceutica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA, Recordati Industria Chimica e Farmaceutica SpA filed Critical Recordati SA
Priority to AU2003276982A priority Critical patent/AU2003276982A1/en
Publication of WO2003106421A2 publication Critical patent/WO2003106421A2/en
Publication of WO2003106421A3 publication Critical patent/WO2003106421A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur des composés, présentant une affinité avec les récepteurs sérotoninergiques, de formule (I), dans laquelle: A est CH ou N; R et R1 sont un grand nombre de substituants; Q est CO, CHOH ou CHOR2; R2 est alkyle; alcényle; alkynyle ou un groupe cycloalkyle, dont chacun est facultativement substitué, ou est alkanoyle, alkanoyoxy, aminocarbonyle, alkylaminocarbonyle, dialkylaminocarbonyle, aminothiocarbonyle, alkylaminothiocarbonyle ou dialkylaminothiocarbonyle; R3 est H, alkyle, alcényle, alkynyle, cycloalkyle, aryle ou un groupe hétérocyclique, dont chacun est facultativement substitué; m est 1 ou 2; R4 est aryle ou hétéroaryle, l'un d'entre eux étant facultativement substitué; R5 est soit (II) soit (III), m étant 1 ou 2; R6 est H ou alkyle; R7 est O, S, NR6 ou CH2; B est une liaison, O, S, NR6 ou CH2; et <u>--------</u> représente une liaison simple ou double. Lesdits composés et leurs énantiomères, diastéréoisomères, oxydes de N-pipérazine, polymorphes, solvates et sels pharmacocompatibles peuvent servir à traiter des patients présentant des dysfonctions neuromusculaires des voies urinaires inférieures, et des maladies liées à l'activité du récepteur 5-HT1A.The invention relates to compounds, having affinity for serotonergic receptors, of formula (I), wherein: A is CH or N; R and R1 are a large number of substituents; Q is CO, CHOH or CHOR2; R2 is alkyl; alkenyl; alkynyl or a cycloalkyl group, each of which is optionally substituted, or is alkanoyl, alkanoyoxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminothiocarbonyl, alkylaminothiocarbonyl or dialkylaminothiocarbonyl; R3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or a heterocyclic group, each of which is optionally substituted; m is 1 or 2; R4 is aryl or heteroaryl, one of which is optionally substituted; R5 is either (II) or (III), m being 1 or 2; R6 is H or alkyl; R7 is O, S, NR6 or CH2; B is a bond, O, S, NR6 or CH2; and <u> -------- </u> represents a single or double bond. Said compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmacocompatible salts can be used to treat patients with neuromuscular dysfunctions of the lower urinary tract, and diseases linked to the activity of the 5-HT1A receptor.

PCT/EP2003/006290 2002-06-14 2003-06-16 Phenylalkylamines and pyridylalkylamines Ceased WO2003106421A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003276982A AU2003276982A1 (en) 2002-06-14 2003-06-16 Phenylalkylamines and pyridylalkylamines with serotoninergic receptor affinity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001329A ITMI20021329A1 (en) 2002-06-14 2002-06-14 NEW OXIALYKYLAMES REPLACED
ITMI2002A001329 2002-06-14

Publications (2)

Publication Number Publication Date
WO2003106421A2 WO2003106421A2 (en) 2003-12-24
WO2003106421A3 true WO2003106421A3 (en) 2004-06-17

Family

ID=29727278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006290 Ceased WO2003106421A2 (en) 2002-06-14 2003-06-16 Phenylalkylamines and pyridylalkylamines

Country Status (4)

Country Link
AU (1) AU2003276982A1 (en)
IT (1) ITMI20021329A1 (en)
TW (1) TW200409632A (en)
WO (1) WO2003106421A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE671440A (en) *
EP0680962A2 (en) * 1994-05-03 1995-11-08 Zeneca Limited Heterocyclic compounds
WO1996016961A1 (en) * 1994-11-28 1996-06-06 American Home Products Corporation (thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
US5585374A (en) * 1992-08-05 1996-12-17 John Wyeth Brother, Limited Amide derivatives
US5610295A (en) * 1993-03-06 1997-03-11 John Wyeth & Brother, Ltd. 4-amino-2-(hetero)aryl-butanamides useful as 5-HT1A -antagonists
US5610164A (en) * 1996-07-24 1997-03-11 American Home Products Corporation (Thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides
EP0924205A1 (en) * 1997-12-16 1999-06-23 Eli Lilly And Company Arylpiperazines having activity at the serotonin 1a receptor
EP0982304A1 (en) * 1998-06-30 2000-03-01 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE671440A (en) *
US5585374A (en) * 1992-08-05 1996-12-17 John Wyeth Brother, Limited Amide derivatives
US5610295A (en) * 1993-03-06 1997-03-11 John Wyeth & Brother, Ltd. 4-amino-2-(hetero)aryl-butanamides useful as 5-HT1A -antagonists
EP0680962A2 (en) * 1994-05-03 1995-11-08 Zeneca Limited Heterocyclic compounds
WO1996016961A1 (en) * 1994-11-28 1996-06-06 American Home Products Corporation (thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
US5610164A (en) * 1996-07-24 1997-03-11 American Home Products Corporation (Thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides
EP0924205A1 (en) * 1997-12-16 1999-06-23 Eli Lilly And Company Arylpiperazines having activity at the serotonin 1a receptor
EP0982304A1 (en) * 1998-06-30 2000-03-01 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems

Also Published As

Publication number Publication date
AU2003276982A1 (en) 2003-12-31
AU2003276982A8 (en) 2003-12-31
ITMI20021329A1 (en) 2003-12-15
WO2003106421A2 (en) 2003-12-24
TW200409632A (en) 2004-06-16

Similar Documents

Publication Publication Date Title
AU624092B2 (en) 3-(4(1-substituted-4-piperazinyl)butyl)-4-thiazolidinones a process for their preparation and their use as medicaments
TNSN04208A1 (en) N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CY1106095T1 (en) PIPERIDINE DERIVATIVES USEFUL AS CHEMOKINE RECEPTOR modulators
RU93004584A (en) TRIAZOLOPIRIDAZIN COMPOUNDS, METHOD FOR THEIR PRODUCTION, APPLICATION, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT
TNSN04073A1 (en) N-SUBSTITUTED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
TNSN06110A1 (en) TRICYCLIC COMPOUNDS AS TRANSPORT INHIBITORS OF GLYCINE
EA200300064A1 (en) CARBOXAMIDE CONNECTIONS AND THEIR APPLICATION AS ANTAGONISTS OF HUMAN 11CBY RECEPTOR
DE69110320D1 (en) Heterocyclic compounds containing nitrogen, their preparation and use.
AR021533A1 (en) DERIVATIVES OF 2,5-DIAZABICICLO [2.2.1] HEPTANE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
MA27573A1 (en) SINOMENIN AND SINOMENIN DERIVATIVES, SYNTHESIS AND USE.
BE903778A (en) DERIVATIVES OF INDOLES.
AU2008304867B2 (en) Indazole acrylic acid amide compound
DE3878371T2 (en) PSYCHOTROPIC BIZYCLIC IMIDES.
FR2856684A1 (en) DIPHENYLPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2003106421A3 (en) PHENYLALKYLAMINES AND PYRIDYLALKYLAMINES
Malawska et al. Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-substituted pyrrolidin-2-one and pyrrolidine derivatives with adrenolytic activity
US5338738A (en) Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
CA2037610A1 (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application
Faghih et al. Structure–activity relationships of non-imidazole H3 receptor ligands. Part 1
RU95122287A (en) NIPECOTINIC ACID DERIVATIVES AS SUBSTANCES THAT IMPEDE THE DISTRIBUTION
DE3920657A1 (en) New 1-cinnamyl-4-(1-phenyl)-cyclo:hexyl)-piperazine - used to inhibit formation of cardiovascular atheroma
MY101352A (en) New benzamides.
DD287496A5 (en) PROCESS FOR THE PREPARATION OF 4-PHENYL-3-BUTENSAEED DERIVATIVES
Xue et al. Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification
JP3240143B2 (en) Cyclic benzylamino, benzylamide and benzylimide derivatives as antipsychotics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP